Article

OncLive Adds Winship Cancer Institute of Emory University to its Strategic Alliance Partnership Program

Author(s):

OncLive will work with Georgia's only NCI-designated cancer center to support its efforts to conduct innovative, multidisciplinary research and translate that knowledge into excellent patient care.

OncLive® is pleased to announce that the Winship Cancer Institute of Emory University has joined its Strategic Alliance Partnership program.

Participating in the Strategic Alliance Partnership program will enable the Winship Cancer Institute of Emory University to work with the OncLive editorial team to raise awareness and enhance the outreach of its collaborative research programs aimed at cancer prevention, prediction, biomarker and therapeutic target discovery, and drug development.

The Winship Cancer Institute of Emory University is a National Cancer Institute-designated cancer center that conducts a wide range of clinical oncology services, translational research initiatives and projects, and patient and professional education programs. Winship is the coordinating center for a vast array of resources in medical, surgical, radiation oncology, diagnostic imaging, and the subspecialties of cancer care throughout Emory University.

Winship scientists and clinical investigators collaborate on a number of developing research programs, including the Cancer Cell Biology Program, which looks at tumor signaling in the context of the tumor microenvironment; the Cancer Prevention and Control Program, which focuses on the entire cancer prevention continuum from primary to secondary to tertiary prevention; the Cancer Genetics and Epigenetics Program, which seeks to enhance our understanding of fundamental genetic alterations that affect tumor development and progression and response to therapy; and the Discovery and Developmental Therapeutics Program, which researches molecular targets for cancer therapy and facilitates translational clinical trials.

Jack Lepping, president of the oncology division of Intellisphere, the publisher of OncLive, said “the Winship Cancer Institute of Emory University is one of the top 50 cancer centers in the United States, with a well-deserved reputation for the highest quality cancer research, treatment, and education programs. We are proud to join with their researchers, clinicians, and other oncology professionals in the fight to help treat, prevent, and save lives from cancer.”

More than 20 cancer centers and schools of nursing have joined OncLive’s Strategic Alliance Partnership program.

To learn more about OncLive®, visit www.OncLive.com.

###

About OncLive®

OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive® and its family of publications is to provide oncology professionals with the resources and information they need in order to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research, and education. To learn more, please visit www.OncLive.com.

About the Winship Cancer Institute of Emory University

The Winship Cancer Institute of Emory University is Georgia's first and only cancer center designated by the National Cancer Institute (NCI). Since 1937, The Winship Cancer Institute has worked tirelessly to prevent, treat and cure cancer.

Media Contact:

Mike Gross

For OncLive

267-932-8760 Ext. 310 (Office)

mike@hornercom.com

Related Videos
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.